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ABSTRACT Prostaglandin E2 (PGE2) regulates nu-
merous biological processes by modulating transcrip-
tional activation, epigenetic control, proteolysis, and
secretion of various proteins. Scar formation depends
on fibroblast elaboration of matrix proteins such as
collagen, and this process is strongly suppressed by
PGE2 through activation of cAMP-dependent protein
kinase A (PKA). However, the actual mechanism by
which PGE2-PKA signaling inhibits collagen expression
in fibroblasts has never been delineated, and that was
the objective of this study. PGE2 unexpectedly induced
a rapid reduction in procollagen I protein expression in
adult lung fibroblasts, with a half-maximum effect at
1.5 h. This effect reflected its inhibition of translation
rather than transcription. Global protein synthesis was
also inhibited by PGE2. This action was mediated by
PKA and involved both activation of ribosomal protein
(rpS6) and suppression of mammalian target of rapa-
mycin (mTOR). Similar effects of PGE2 were demon-
strated in mouse peritoneal macrophages (PMs). These
findings identify inhibition of translation as a new
mechanism by which PGE2 regulates cellular function
and a novel example of translational inhibition medi-
ated by opposing actions on two distinct translational
control pathways. Translational inhibition would be ex-
pected to contribute to dynamic alterations in cell func-
tion that accompany the changing PGE2 levels observed in
disease states and with various pharmacotherapies.—
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Fibrotic tissue remodeling is the consequence of an
aberrant repair response to injury. Fibrotic diseases affect
virtually all vital organs, impair normal organ function, are
largely irreversible without any effective treatment, and are a
leading cause of morbidity andmortality (1). New therapeu-
tic strategies for these disorders are desperately needed and
may be informed by a better understanding of how scar
formation is regulated. Fibroblasts are the primary effector
cells responsible for elaborating matrix proteins such as
collagen I, the predominant type of collagen produced by
lung fibroblasts (2), which comprise the scar. The suppres-
sion of collagen I production by fibroblasts is an attractive
strategy for preventing or halting this process (1).
Prostaglandin E2 (PGE2) is a pleiotropic lipid medi-
ator that is well known to suppress most fibroblast
functions, including collagen production (3–12). In-
deed, an impairment in lung synthesis of PGE2 is
associated with and very likely facilitates the develop-
ment of pulmonary fibrosis (13, 14). The suppressive
actions of PGE2 in fibroblasts are mediated by its ability
to increase intracellular cAMP production after bind-
ing to its Gs-coupled receptors EP2 and EP4 (9, 11).
cAMP activates 2 downstream effectors: protein kinase
A (PKA) and guanine nucleotide exchange protein
activated by cAMP (Epac). PKA and Epac have both
redundant and nonredundant roles in PGE2’s regula-
tion of cell functions. For example, we have shown in
lung fibroblasts that PKA is responsible for suppressing
expression of collagen I and that Epac is responsible for
inhibiting cell proliferation (10). However, the actual
mechanism by which PGE2-PKA signaling reduces col-
lagen I protein levels remains unknown.
Steady-state levels of any cellular protein are deter-
mined by the balance of the processes of transcription,
translation, and degradation. There are conflicting
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reports regarding PGE2 or cAMP regulation of mRNA
expression of collagen I. An early study showed a
reduction, albeit modest, of collagen I mRNA expres-
sion in lung fibroblasts (15), and a subsequent one
showed no or only minimal effects (16). Degradation of
collagen can be mediated by matrix metalloproteinases
(MMPs) that possess collagenase activity. Data regard-
ing the effects of PGE2 on MMPs in fibroblasts are
similarly conflicting. For example, PGE2 was reported
to increase MMP-2 expression and activity in WI-38
lung fibroblasts (16), but to have no effect on MMPs in
human fetal lung (HFL)-1 fibroblasts (17). These lim-
ited data therefore suggest that PGE2 regulation of
collagen I protein expression in lung fibroblasts is
independent of its effects on transcription or MMP-
dependent extracellular degradation.
In the current study, we sought to clarify the mech-
anisms by which PGE2 regulates collagen I expression
in lung fibroblasts. We report that both endogenous
and exogenous PGE2, via PKA signaling, suppressed
translation of collagen I and global protein synthesis.
Protein translation is well known to be enhanced by
mammalian target of rapamycin (mTOR; reviewed in
ref. 18), but data are conflicting regarding its suppres-
sion by ribosomal protein S6 (rpS6; 19, 20). In the
current study, PGE2 inhibited mTOR while activating
rpS6, and both of these regulatory events contributed
to inhibition of collagen synthesis. PGE2 had similar
effects on these two translational control pathways and
on translation itself in macrophages, the key effector
cells of inflammatory and innate immune responses.
Inhibition of translation provides a novel means by
which PGE2 can regulate diverse cellular functions, in-
cluding fibrogenesis. Our findings also predict that
changes in protein translation accompany alterations in
tissue levels of PGE2 observed in disease states, such as
fibrosis, infection, inflammation, and cancer, and in re-
sponse to commonly used medications, such as glucocor-
ticoids and nonsteroidal anti-inflammatory agents.
MATERIALS AND METHODS
Reagents
Primary antibodies (Abs) for immunoblot analysis were ob-
tained from the following suppliers: anti-human type I colla-
gen for immunoblot analysis from CedarLane Laboratories
(Burlington, ON, Canada) and for immunoprecipitation
from Abcam (Cambridge, MA, USA) (both Abs predomi-
nantly detect a band for procollagen I, as described in
Results); anti-GAPDH from Santa Cruz Biotechnology (Dal-
las, TX, USA); anti-total and anti-phosphorylated rpS6 and S6
kinase 1 (S6K1), anti-total binding protein-1 of eukaryotic
initiation factor 4E (4E-BP1), and anti-X-chromosome-linked
inhibitor of apoptosis (XIAP) from Cell Signaling Technolo-
gies (Danvers, MA, USA); and anti-cystatin C from Merck
Millipore (Billerica, MA, USA). Secondary anti-rabbit and
anti-murine Abs for immunoblot analyses were from Cell
Signaling Technologies. Nonspecific control rabbit IgGs for
immunoprecipitation were obtained from Santa Cruz Bio-
technology. Protein A Sepharose for immunoprecipitation
was from GE Healthcare (Little Chalfont, UK). Myristoylated
PKA inhibitory peptide 14–22 (PKI), cycloheximide (CHX),
and the nonselective cyclooxygenase (COX) inhibitor aspirin
[acetylsalicylic acid (ASA)] were purchased from Sigma-
Aldrich (St. Louis, MO, USA). PGE2 and the EP2 antagonist
PF-04418948 were obtained from Cayman Chemicals (Ann
Arbor, MI, USA) and dissolved in DMSO. Control siRNA and
siRNA targeting rpS6 were On-Target plus Smart pool prod-
ucts from Thermo Scientific (Waltham, MA, USA). Dulbecco’s
modified Eagle’s medium (DMEM), methionine-free DMEM,
RPMI 1640, Opti-MEM I reduced-serum medium, RNAiMAX
for siRNA transfection, Click-IT l-azidohomoalanine (AHA)
for nascent protein synthesis, and the Click-IT Biotin Protein
Analysis Detection Kit were purchased from Life Technolo-
gies (Carlsbad, CA, USA). The PGE2 ELISA kit was obtained
from Enzo Life Sciences (Farmingdale, NY, USA), the pro-
tease inhibitor from Roche (Basel, Switzerland), and the
Phosphatase Inhibitor Cocktail Set I and II from Calbiochem-
Novabiochem (Beeston, UK).
Human lung fibroblast culture
Human adult fibroblasts from normal lung (CCL210) and
HFL fibroblasts (IMR-90) were purchased from American
Type Culture Collection (Manassas, VA, USA). The cells were
cultured at 37° in 5% CO2. The HFL fibroblasts were cultured
in DMEM supplemented with 10% fetal bovine serum (FBS;
Thermo Scientific) and 1% penicillin/streptomycin and were
used in experiments at passages 6–10. No apparent change in
fibroblast responsiveness to PGE2 was noted during cell
passage. Human fibroblasts were plated in Falcon 6-well
plates (BD Biosciences, San Jose, CA, USA) at 5  105
cells/well, or at 2–3  105 cells/well for RNA silencing. They
were allowed to adhere for 8–10 h in serum-containing
DMEM and then cultured in serum-free DMEM for 16–20 h.
After the medium was removed, the cells were treated as
indicated. Cell lysates were obtained with lysis buffer consist-
ing of PBS with 1% Nonidet P-40, 0.5% sodium deoxycholate,
0.1% SDS, 1 protease inhibitor, and 1:100 dilution of
Phosphatase Inhibitor Cocktail Set I and II (21).
Animals
Naive C57BL/6 male mice (8–12 wk) were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA) and bred in
the University of Michigan Unit for Laboratory Animal Med-
icine. The animals were treated according to U.S. National
Institutes of Health guidelines for the care and use of
experimental animals, with the approval of the University of
Michigan Committee for the Use and Care of Animals.
Culture of mouse peritoneal macrophages (PMs)
Residentmouse PMs were isolated by lavage of the peritoneal cavity
with 5 ml PBS (22). The PMs were incubated in RPMI 1640 (Life
Technologies) supplemented with 10% FBS and 1% penicillin/
streptomycin for 2 h at 4–6  106 cells/well and were allowed to
adhere to plastic 6-well plates. The cells were washed twice with
serum-free medium for removal of nonadherent cells and were
then treated as indicated in serum-free medium.
RNA silencing
CCL210 human adult lung fibroblasts were incubated with 50 nM
of rpS6-targeting or control siRNA plus 5 l RNAiMAX in 2 ml
Optimem I (Life Technologies) reduced-serum medium without
antibiotics. After 72 h, cells were washed twice with serum- and
antibiotic-free DMEM, then incubated in serum-free DMEM with
antibiotics in the presence or absence of PGE2 at 500 nM for 4 h.
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Quantitative PCR and RNA isolation
Cells were suspended in 1 ml Trizol (Life Technologies), and
RNA was extracted (21). RNA was amplified by quantitative
RT-PCR performed with a SYBR Green PCR kit (Life Technol-
ogies) on an ABI Prism 7300 thermocycler (Life Technologies).
Relative gene expression was determined by the CT method,
with -actin used as the reference gene. Primer sequences were
as follows: COL1A1 forward, 5=-GGGCAAGACAGTGATT-
GAATA-3=, reverse, 5=-ACGTCGAAGCCGAATTCCT-3=);
COL1A2 forward, 5=-TCTCTACTGGCGAAACCTGTA-3=, re-
verse, 5=-TCCTAGCCAGACGTGTTTCTT-3= (23), and -actin
forward, 5= -GCCACGGCTGCTTCCA-3=, reverse, 5= -
GAACCGCTCATTGCCATTG-3= (9).
Immunoblot analysis
Protein (12–25 g) in scraped cell lysates containing both
intracellular and extracellular proteins was loaded for elec-
trophoresis, and subsequent immunoblot and densitometric
analyses were performed (21) with the primary Abs described
earlier. Densitometric values of bands for procollagen I were
normalized to GAPDH detected in the same membrane, and
relative levels of procollagen I were expressed as defined in
the figure legends. Based on the molecular mass of target
proteins, 8, 10, or 12.5% acrylamide gels were used. For
normalization of p-S6K1 or p-rpS6 to total S6K1 or total rpS6,
respectively, an amount of lysate protein identical with that
used for immunoblot against phosphorylated protein was
loaded on another parallel gel for electrophoresis, and total
protein expression was detected by immunoblot analysis.
Detection of nascent proteins
Newly synthesized proteins were detected by using the
Click-IT method (Life Technologies) according to the man-
ufacturer’s instructions. In brief, cells were incubated in
methionine-free DMEM for 30 min before being pulsed with
the nonradioactive, azide-containing methionine analog AHA
for 40 min. Click-IT chemistry was subsequently used to biotin
conjugate the methionine analog incorporated in the pro-
teins. After electrophoresis of cell lysates on 8 or 10%
acrylamide gels and transfer of proteins onto the membranes,
streptavidin-HRP was applied to the membranes to detect
newly synthesized proteins that contained biotin-conjugated
AHA.
Immunoprecipitation
For procollagen I immunoprecipitation, cell lysates were
incubated overnight at 4°C with anti-collagen I Ab or control
rabbit IgG (both at 2.5 g/ml). Protein A-Sepharose was
added and incubated for 3–4 h with rotation at 4°C, and
immunoprecipitates were isolated and subjected to electro-
phoresis, as described previously (24). Total protein (80–
120 g) after Click-IT reaction was used for immunopre-
cipitation, and immunoprecipitates were subjected to
electrophoresis and immunoblot analysis to detect both
total procollagen I and newly synthesized procollagen I
containing biotin-conjugated AHA.
Statistical analyses
Data are presented as means  sem of values determined
from 3 experiments or, in some instances, actual values
from 2 experiments. Data analysis was performed with Prism
software (GraphPad, San Diego, CA, USA), using Student’s t
test or ANOVA with Tukey’s or Dunnett’s multiple-compari-
son test, as appropriate, to determine significant differences
between group means. In all instances, statistical significance
was inferred from a value of P  0.05.
RESULTS
Rapid suppression by PGE2 of procollagen I protein
expression in adult lung fibroblasts
It should be noted that the anti-collagen I Ab used
detects a single or a predominant band at a molecular
mass between 150 and 250 kDa, which actually corre-
sponds to the immature form of collagen I, termed
procollagen I, and we have designated this band as
procollagen I throughout the article. Procollagen I is
synthesized intracellularly and forms a triple helix
composed of two 1 chains and an 2 chain. After its
secretion into the extracellular space, procollagen I
undergoes removal of extension peptides to form ma-
ture collagen I and subsequently collagen fibrils. Pro-
collagen I is the molecular species that is susceptible to
regulation at the biosynthetic and degradative levels,
and such regulation results in changes in mature
collagen I levels (25).
We first examined the time course of PGE2-induced
suppression of collagen I protein expression in CCL210
adult lung fibroblasts obtained from histologically nor-
mal lung. Surprisingly, PGE2 at 500 nM, a concentra-
tion that we previously reported leads to maximum
suppression of collagen I expression after overnight
incubation (18–20 h) in normal adult (9) or HFL (10)
fibroblasts, unexpectedly decreased procollagen I pro-
tein expression very quickly, with a statistically signifi-
cant effect observed as early as 1 h, a half-maximum
effect at 1.5 h, and a maximum effect of 90%
reduction within 8 h (Fig. 1A). We also confirmed the
dose-dependent ability of PGE2 to elicit a rapid suppres-
sion of procollagen I protein expression at the 4 h time
point (Fig. 1B). Effects of PGE2 at 4 h were detectable
at 1–10 nM, half-maximum at 100 nM, and maximum
at 250–1000 nM. The shape of this dose–response
relationship paralleled that which we had observed for
overnight incubations (9, 10). Since PGE2 exerted its
maximum suppressive effect on procollagen I expres-
sion at 500 nM, we used this concentration in subse-
quent mechanistic experiments, unless otherwise indi-
cated. As mentioned above, procollagen I is composed
of two 1 chains and an 2 chain (26), and we therefore
sought to clarify the effect of PGE2 on levels of mRNA
encoding both procollagen I 1 (ColIA1) and 2 (Co-
lIA2). PGE2 had no substantial inhibitory effects on
mRNA expression of either ColIA1 or ColIA2 at time
points ranging from 1 to 24 h (Fig. 1C), indicating that
PGE2 reduces procollagen I protein expression at a
posttranscriptional level. We speculate that the appar-
ent increase in ColIA2 mRNA at 24 h represents an
attempt to compensate for the reduction in its protein
level.
PGE2 is the predominant endogenous prostanoid
product of normal lung fibroblasts (14), and we there-
fore evaluated whether endogenous PGE2 regulates
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procollagen I protein expression in a manner similar to
the exogenously added prostanoid. Serum contains
numerous growth factors that increase expression of
inducible COX-2 and subsequent PGE2 production in
fibroblasts (27). After overnight serum starvation, cells
were incubated in fresh medium for various intervals,
with or without 10% FBS, and in the presence or
absence of the COX inhibitor ASA, and PGE2 concen-
trations in the supernatants and procollagen I protein
expression in the cell lysates were examined. The PGE2
content of the supernatants was markedly increased by
6 h after addition of serum-containing medium (Sup-
plemental Fig. S1A), and a parallel reduction in pro-
collagen I protein expression was observed at 6 h (Fig.
1D and Supplemental Fig. S1B). Both the induction of
PGE2 and the inhibition of procollagen I were com-
pletely reversed by simultaneous administration of ASA
at 400 M (Supplemental Fig. S1). ASA likewise inhib-
ited serum suppression of procollagen I at the lower
dose of 200 M (Fig. 1D). The inhibitory effect of ASA
on serum suppression of procollagen I was dose de-
pendently overcome by exogenous PGE2 (Fig. 1D).
Figure 1. Rapid suppression by PGE2 of pro-
collagen I protein expression in normal adult
lung fibroblasts. A–C) After overnight serum
starvation, cell culture medium was changed
to fresh serum-free medium, and normal adult lung fibroblasts were then incubated with or without PGE2 (at 500 nM in
A and at various concentrations in B). A, B) Time course (A) and dose dependency (B) of the effect of PGE2 on procollagen
I protein expression. At each time point after addition of PGE2 at the indicated concentrations, cell lysates were harvested,
and procollagen I levels in the lysates were determined by immunoblot analysis with densitometry. Left panel:
representative immunoblot. Right panel: results of densitometric analysis of procollagen I levels from 3–5 experiments (A)
or 3 experiments (B). After normalization to GAPDH, the procollagen I level in PGE2-treated cells was expressed relative
to that in cells without PGE2 (expressed as 100%, dashed line) at each time point in each experiment. Data represent
means  sem. C) PGE2 did not suppress collagen I mRNA expression. At the indicated time points, ColI1 (left panel) and
ColI2 (right) mRNA levels in cell lysates were determined by semiquantitative real-time RT-PCR and then were expressed
relative to the level in the no-PGE2 control condition (expressed as 100%, dashed line) at each time point in each
experiment. Data are expressed as means sem from 4–5 (left panel) or 3–4 (right panel) experiments. *P 0.05, **P 0.01,
***P  0.001 vs. control fibroblasts without PGE2 treatment. D, E) Serum decreased procollagen I protein expression via
the PGE2-EP2 pathway. After cells were serum starved overnight, serum-free medium was removed, and cells were incubated
in serum-containing medium, with or without aspirin (200 M) (or its vehicle DMSO at a final concentration of 0.2%) in
the absence or simultaneous presence of PGE2 (10 or 500 nM; D), or with or without the EP2 antagonist PF-04418948 (1
nM; E) for 6 h. Then collagen I protein levels in the cell lysates were determined by immunoblot analysis. Immunoblot
representative of 3 experiments is shown. Lanes separated by the vertical dashed line were from the same blot, but were not
contiguous in the original gel. After normalization to GAPDH, the procollagen I level in PGE2-treated cells was expressed
relative to that in cells treated without serum (expressed as 100%) in each experiment (E). Data represent means  se.
*P  0.05 vs. control fibroblasts without serum treatment.
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There are 4 receptors for PGE2 [E prostanoid (EP)
1–4], and the suppressive effect of PGE2 on procolla-
gen I protein levels is mainly mediated via ligation of
the Gs-coupled EP2 receptor in normal lung fibro-
blasts (9). To determine whether the effect of serum
described above is also mediated by PGE2-EP2 signal-
ing, we used a newly developed, potent, selective EP2
antagonist, PF-04418948 (28). This EP2 antagonist re-
versed serum suppression of procollagen I protein
expression, as did ASA (Fig. 1E). These results demon-
strate that endogenous PGE2 shares with exogenous
PGE2 the ability to rapidly decrease procollagen I
protein expression in adult lung fibroblasts.
PGE2 suppressed procollagen I protein synthesis by
inhibiting its translation in adult lung fibroblasts
Posttranscriptional regulation of procollagen I protein
by PGE2 could be directed at either translation or
degradation steps. We assessed the effects of PGE2 on
turnover of procollagen I protein in cells pretreated for
30 min with CHX, a well-known protein translation
inhibitor. In the absence of PGE2, procollagen I pro-
tein decreased in CHX-treated fibroblasts with a half-
life of 1.5 h, and turnover was essentially complete by
4.5 h (Fig. 2A). It should be noted that because CHX
was added 30 min before PGE2, the time points indi-
cated in Fig. 2A, B actually reflect an additional 30 min
of incubation in CHX. Such a rapid turnover of pro-
collagen I protein is in fact consistent with results
reported previously (reviewed in refs. 29, 30). The
addition of PGE2 to CHX-treated cells had no further
effect on procollagen I turnover, indicating a failure of
the prostanoid to directly influence degradation of this
protein. We obtained similar results with another trans-
lation inhibitor, puromycin (Supplemental Fig. S2).
Data presented thus far are limited to the regulation
of basal expression of procollagen I, but fibroblasts are
Figure 2. Inhibition by PGE2 of collagen I protein translation in normal adult lung fibroblasts. A) Rapid suppression of collagen
I protein expression by CHX and PGE2. After overnight serum starvation, cells were cultured in serum-free medium with or
without the translation inhibitor CHX (10 M), PGE2 (500 nM), or both. CHX was added first, and 30 min later, PGE2 was
added to the indicated wells without changing the medium. At the indicated time points after addition of PGE2, cell lysates were
harvested, and collagen I levels in cell lysates were determined by immunoblot analysis with densitometry. Left panel:
representative immunoblot. Right panel: results of densitometric analysis of collagen I levels from 5 experiments. After
normalization to GAPDH, collagen I was expressed relative to that in control without PGE2 at each time point in each
experiment. Data represent means  se. ***P  0.001 vs. control fibroblasts without PGE2 treatment;
		P  0.01, 			P 
0.001 between indicated groups. B) Rapid suppression by PGE2 and CHX of TGF--enhanced collagen I protein expression.
After overnight serum starvation, medium was changed, and cells were treated with or without TGF- (2 ng/ml) for 24 h.
Following removal of medium, cells were incubated in fresh serum-free medium with or without PGE2 (500 nM) or CHX (10
M) for 4 h, after which cell lysates were harvested, and collagen I levels in cell lysates were determined by immunoblot analysis.
Immunoblot representative of 2 experiments is shown. C) Suppression by PGE2 of translation of collagen I protein in normal
adult lung fibroblasts. After overnight serum starvation, cells were washed once with methionine- and serum-free medium, and
then were cultured in methionine- and serum-free medium with or without PGE2 (500 nM) for 30 min. Methionine analog AHA
was added at final concentration 25 M into each well, and cells were further incubated with AHA for 40 min. Cell lysates were
harvested, and Click-iT reaction was performed on cell lysates to conjugate biotin to the AHA analog incorporated into newly
synthesized proteins. After immunoprecipitation with anti-collagen I Ab, immunoprecipitates were electrophoresed, and total
collagen I protein expression was first determined by immunoblot analysis (top panel). Then, anti-collagen I Ab was stripped
from the membrane, and newly synthesized collagen I protein containing biotin-conjugated AHA was detected with
streptavidin-HRP (bottom panel). Immunoblot is representative of 3 experiments.
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well known to up-regulate their production of extracel-
lular matrix proteins in response to profibrotic growth
factors, such as TGF-. We therefore determined the
effects of PGE2 and CHX on TGF--stimulated procol-
lagen I protein expression. Under these conditions,
both PGE2 and CHX elicited a marked reduction in
procollagen I protein within 4 h (Fig. 2B). Together,
these results strongly suggest that PGE2 suppresses
collagen I protein expression via the same pathway as
does CHX—namely, inhibition of translation.
We sought to confirm this finding directly by study-
ing the effect of PGE2 on newly synthesized procollagen
I protein. After a 30 min preincubation with or without
PGE2 in methionine-free medium, fibroblasts were
pulsed with the nonradioactive methionine analog AHA for
40 min, after which the cell lysates were harvested. A
commercially available kit to detect protein synthesis
(Click-iT; Invitrogen) was used to biotin conjugate the
methionine analog incorporated into proteins and
streptavidin-HRP, to detect proteins synthesized during
the methionine analog pulse. Procollagen I protein in
lysates was purified by immunoprecipitation with anti-
collagen I Ab. After electrophoresis of immunoprecipi-
tates, total and newly synthesized procollagen I proteins
were detected with anti-collagen I Ab or with strepta-
vidin-HRP, respectively. As shown in Fig. 2C, PGE2
strongly suppressed incorporation of methionine an-
alog into procollagen I protein, representing an
inhibitory effect on neosynthesis of procollagen I
during this brief period of pulse labeling. These data
strongly support the conclusion that PGE2 suppresses
procollagen I synthesis at the level of translation.
PGE2 suppressed global protein synthesis in
fibroblasts
We next used the Click-iT system to examine the effect
of PGE2 on global protein synthesis. CCL210 adult lung
fibroblasts were treated as in Fig. 2C, with or without
PGE2 or CHX, for 30 min, followed by a 40-min pulse
with methionine analog. Cell lysates were harvested and
subjected to gel electrophoresis, and newly synthesized
proteins transferred to the membrane were detected
with streptavidin-HRP and quantitated by densitometry
of the entire lane (Fig. 3A). CHX strongly (75%)
suppressed neosynthesis of total proteins, as expected,
whereas the suppressive effect of PGE2 was of lesser
magnitude (30%), but nonetheless significant. Whereas
CHX uniformly reduced the density of all protein
bands (Supplemental Fig. S3), the inhibitory effect of
PGE2 on synthesis of individual protein bands was
variable.
The effect of PGE2’s ability to inhibit translation on
steady-state protein levels would be expected to be
magnified in proteins with rapid turnover, similar to
procollagen I. We therefore also examined its effect on
steady-state levels of two additional proteins known to
have a short half-life: XIAP and cystatin C. As was the
case for procollagen I, PGE2 decreased expression of
XIAP (Fig. 3B) and cystatin C (Fig. 3C) within 1–2 h. A
reduction in XIAP synthesis by CHX has been observed
to be necessary for Fas ligand to induce apoptosis in
fibroblasts (31). Taken together, these data demon-
strate that PGE2 suppresses global protein synthesis in
adult lung fibroblasts.
Figure 3. PGE2 inhibition of global protein synthesis in fibroblasts at the translation step. A) PGE2 inhibition of global protein
synthesis. After overnight serum starvation, normal adult lung fibroblasts were washed once with methionine- and serum-free
medium and then were cultured in methionine- and serum-free medium, with or without PGE2 (500 nM) or CHX (10 M) for
30 min. Methionine analog AHA was added at final concentration of 25 M into each well, and cells were further incubated with
AHA for 40 min. Then, cell lysates were harvested, and a Click-iT reaction was performed on cell lysates to conjugate biotin to
AHA analog incorporated into newly synthesized proteins. After electrophoresis of the cell lysates, newly synthesized proteins
containing biotin-conjugated AHA were detected with streptavidin-HRP. Left panel: representative immunoblot. Right panel:
results of densitometric analysis from 5–6 experiments. Densitometry of the entire lane is expressed relative to that in
control without any treatment (expressed as 100%, dashed line) in each experiment. ***P  0.001 vs. no-treatment
control. B, C) Suppression by PGE2 of expression of short half-life proteins other than collagen I in normal lung fibroblasts.
After overnight serum starvation, cells were incubated in fresh serum-free medium, with or without PGE2 (500 nM). At the
indicated time points after addition of PGE2, the cell lysates were harvested, and XIAP (B) and cystatin C levels (C) were
detected by immunoblot analysis. Immunoblot is representative of 3 experiments.
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PGE2 suppressed the mTOR pathway and activated
rpS6 in fibroblasts
Translation initiation is the rate-limiting step in protein
synthesis, and one of its key controllers is mTOR. This
serine/threonine kinase is the catalytic subunit of
mTOR complexes (mTORCs) 1 and 2. Each complex
has distinct roles in regulation of cell functions (18),
with mTORC1 recognized as a key promoter of trans-
lation initiation via its phosphorylation of the substrates
S6K1 and 4E-BP1. We first asked whether PGE2 sup-
presses mTORC1 activity, by assessing its effects on
phosphorylation of S6K1 and 4E-BP1. Indeed, PGE2
reduced phosphorylation of both of these mTOR sub-
strates within 5 to 10 min (Fig. 4A). Although the rate
of dephosphorylation of both substrates was similar to
that elicited by the well-established mTORC1 inhibitor
rapamycin, the extent of dephosphorylation was slightly
less (Fig. 4C). By contrast, PGE2 reduced collagen I
protein expression at early time points to a greater
extent than did rapamycin (Fig. 4D). Moreover, the
inhibitory effects of PGE2 on procollagen I protein
expression were additive to those of rapamycin at 4 h
(Fig. 4D, right panel). These comparative results with
rapamycin suggest that, although PGE2 inhibits mTORC1,
this action is unlikely to fully explain its inhibition of
procollagen I synthesis.
Active S6K1 phosphorylates and activates 3 distinct
downstream substrates that influence protein transla-
tion. Among these, eukaryotic initiation factor 4B (eIF4B)
and eukaryotic elongation factor 2 (eEF2) promote
Figure 4. PGE2 suppressed phosphorylation of mTOR substrates while enhancing phosphorylation of rpS6 in normal adult lung
fibroblasts. A–C) PGE2-induced suppression of the mTOR pathway along with enhancement of phosphorylation of rpS6. After
overnight serum starvation, serum-free medium was changed, and cells were incubated with or without PGE2 (500 nM) or
rapamycin (1 M). At the indicated time points, cell lysates were harvested, and total and phosphorylated S6K1, 4E-BP1, and
rpS6 levels in cell lysates were determined by immunoblot analysis. A) Representative immunoblot for PGE2 regulation of the
mTOR pathway and rpS6. B) Densitometric ratios of phospho:total S6K1 and rpS6 at 15 min after addition of PGE2, expressed
relative to that in control fibroblasts without PGE2 treatment. Dashed line indicates 100%. Data were obtained from 5
experiments and are expressed as means  sem. **P  0.01, ***P  0.001 vs. control fibroblasts without PGE2. C) Comparison
of regulation by PGE2 vs. rapamycin (Rapa) of mTOR substrates and rpS6. Immunoblot for phosphorylation of mTOR
substrates and rpS6 representative of 3 experiments is shown. D) Stronger suppression of collagen I protein expression by PGE2
than by rapamycin. After overnight serum starvation, medium was changed, and cells were cultured in serum-free medium, with
or without rapamycin (1 M) and PGE2 (500 nM). Rapamycin was added first; 30 min later, PGE2 was added where indicated
without changing the medium. At the indicated time points after addition of PGE2, cell lysates were harvested, and collagen I
levels in the cell lysates were determined by immunoblot analysis with densitometry. Left panel: representative immunoblot.
Right panel: results of densitometric analysis of collagen I levels in 3–5 experiments. After normalization to GAPDH, collagen
I was measured relative to that in the no-PGE2 control at each time point in each experiment. Data represent means  se.
*P  0.051, **P  0.01,***P  0.001 vs. control fibroblasts without PGE2 treatment;
	P  0.05, 		P  0.01 between indicated
groups. E) Suppression by PGE2 of collagen I protein levels in normal adult lung fibroblasts was blunted by siRNA that targets
rpS6. After incubation of cells in Optimem serum-free medium with control siRNA or siRNA targeting rpS6 for 3 d, cells were
either harvested to determine the efficiency of silencing the target protein or were further incubated in serum-free DMEM, with
or without PGE2 (500 nM), for 4 h. Cell lysates were collected, and collagen I levels in the lysates were determined by
immunoblot analysis. Left panel: reduction of rpS6 protein expression with siRNA specific for rpS6. Right panel: effect of
silencing of rpS6 on PGE2-induced suppression of collagen I protein expression. Immunoblot is representative of 3 experiments.
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protein translation, whereas rpS6 inhibits it (reviewed
in refs. 19, 20). Thus, the net effect of S6K1 on protein
translation can be defined by the balance between
eIF4B and eEF2 vs. rpS6 pathways. S6K1 dephosphory-
lation would be expected to concomitantly reduce
phosphorylation of its substrate rpS6, and this was
indeed the observed effect of rapamycin (Fig. 4C). By
contrast, PGE2 caused a marked increase in phosphor-
ylation of rpS6, despite the inhibited activation of S6K1
(Fig. 4A–C). Enhancement of rpS6 phosphorylation by
PGE2 was dose dependent (Supplemental Fig. S4A)
over the same concentration range at which procolla-
gen I was suppressed and lasted for more than 8 h
(Supplemental Fig. S4B). We concluded that this dis-
tinctive ability of PGE2 to phosphorylate and thereby
activate rpS6 could represent an mTORC1-indepen-
dent mechanism contributing to PGE2 inhibition of
procollagen I synthesis. To evaluate this possibility,
rpS6 was knocked down with siRNA. The 50% knock-
down of rpS6 protein abrogated the inhibitory effect of
PGE2 on procollagen I levels (Fig. 4E). Activation of the
translation suppressor rpS6 is thus a mechanism for
PGE2 inhibition of procollagen I synthesis that is not
shared by rapamycin and one that can explain how
PGE2 potentiates rapamycin’s effects. These data dem-
onstrate that PGE2 suppresses procollagen I protein
synthesis by both inhibiting mTORC1 and activating
rpS6.
PKA mediated PGE2-induced suppression of
mTORC1 as well as activation of rpS6
We previously identified PKA as the primary cAMP
effector that mediates PGE2-induced suppression of
procollagen I expression in normal lung fibroblasts
(10). In the current study, we confirmed that a PKA
inhibitor attenuates the rapid (within 4 h) suppression
by PGE2 of procollagen I expression (Fig. 5A), just as
we had reported it to attenuate the suppression of
procollagen I after 20 h incubation with PGE2 (10). We
next sought to clarify the role of PKA in PGE2 regula-
tion of the pathways controlling protein synthesis, as
described in Fig. 4, and found that a PKA inhibitor
likewise attenuated both the PGE2-induced suppression
of mTOR activity (as assessed by monitoring phosphor-
ylation of S6K1; Fig. 5B) and its enhancement of
phosphorylation of rpS6 (Fig. 5C). These data impli-
cate PKA as the primary effector downstream of PGE2,
which is responsible for inhibiting protein translation
through both of these control pathways.
PGE2 suppressed global protein synthesis in
macrophages
Macrophages have pleiotropic roles in both homeosta-
sis and inflammation (32), and, like fibroblasts, many
of their activation functions are suppressed by PGE2
(reviewed in refs. 33, 34). We therefore asked whether
PGE2 has inhibitory effects on protein synthesis in
macrophages similar to those in fibroblasts. Indeed,
PGE2 significantly suppressed new protein synthesis
(Fig. 6A) in mouse PMs, and this effect was associated
with suppression of mTORC1 activity and enhance-
ment of rpS6 phosphorylation (Fig. 6B). However, the
magnitude of these PGE2 effects was more modest than
observed in fibroblasts. Thus, these results suggest that
regulation by PGE2 of pathways controlling protein
translation is not limited to fibroblasts and is likely to be
generalizable, to some degree; however, cell specificity
may pertain in the magnitude of these effects.
DISCUSSION
In our study, PGE2, themost abundant and well studied of
the prostanoid family of COX-derived lipid mediators,
inhibited translation of proteins in fibroblasts and macro-
phages. This action was mediated by PKA and involved
divergent regulation of two distinct pathways controlling
translation initiation: suppression of the permissive
mTORC1 pathway and activation of the inhibitory rpS6
pathway (as depicted in Fig. 6C). These findings provide a
novel paradigm for understanding how this ubiquitous
prostanoid regulates diverse cell functions.
mTORC1 is recognized as a master regulator of
protein translation. Of interest, the suppressive effects
Figure 5. Actions of PGE2 in lung
fibroblasts were attenuated by a PKA
inhibitor. After overnight serum
starvation, serum-free medium was replaced, and cells were preincubated with or without the PKA inhibitor myr-PKI (10
M; refs. 14–22) for 2 h. PGE2 (500 nM) was added, and cell lysates were harvested at the indicated time points after
addition of PGE2. Levels of collagen I (A), phospho-S6K1 (B), and phospho-rpS6 (C) in cell lysates at the indicated time
points were determined by immunoblot analysis. PKA inhibitor interfered with PGE2-induced suppression of collagen I (A)
and phospho-S6K1 (B) levels, as well as enhancement of phorpho-rpS6 (C). Immunoblot is representative of 2 experiments.
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of the well-known mTORC1 inhibitor rapamycin on
steady-state levels (Fig. 4D) of procollagen I protein
were weaker than those of PGE2. These findings sug-
gested that PGE2 inhibits protein synthesis by modulat-
ing an additional translational control pathway other
than mTORC1. In this regard, we found that PGE2
strongly enhanced phosphorylation (and hence activa-
tion) of rpS6 (Fig. 4A–C). Moreover, knockdown of
rpS6 interfered with PGE2-induced reduction of procol-
lagen I (Fig. 4E). These results suggest that activation of
rpS6 is more important for PGE2-mediated reduction
of procollagen I protein expression in lung fibroblasts
than is suppression of the mTOR pathway. The role of
rpS6 in the control of protein translation has been
somewhat controversial. Although rpS6 was once thought to
facilitate translation, recent data suggest instead that it
functions as a negative regulator of translation, serving
to restrain energy waste in certain settings of mTORC1
activation (20). Our findings lend support to rpS6’s
functioning in a negative regulatory role in this exper-
imental system.
S6K1 is a critical regulator of phosphorylation of
rpS6, and generally, phosphorylation/activation of
rpS6 parallels that of S6K1. This pattern is the same as
that observed with rapamycin treatment. However,
PGE2 paradoxically enhanced phosphorylation of rpS6
while suppressing that of S6K1. To our knowledge,
PGE2 is the first example of a single substance’s mod-
ulating phosphorylation of rpS6 and S6K1 in opposing
directions. PKA was implicated in both of these actions
of PGE2 (Fig. 5A, B), and PKA has notably been shown
to be capable of phosphorylating rpS6 independent of
S6K1 (35). Indeed, the program GPS 2.0 (http://
gps.biocuckoo.org/down.php) indicates that the S235/
S236 residues of rpS6 (whose phosphorylation we as-
sayed in this study) are candidates for direct phospho-
rylation by PKA. Such a direct role for PKA in our
system remains to be established.
The conclusion that PGE2 suppresses mTORC1 was
based on its ability to suppress phosphorylation of two
mTORC1 substrates: S6K1 and 4E-BP1. Studies of a
PKA inhibitor implicated PKA in these PGE2 effects.
Since mTORC1 is a well-known inhibitor of autophagy
(18), suppression of mTORC1 by the PGE2-PKA axis
would be predicted to promote autophagy, reflecting
yet another novel mechanism for the regulation of cell
Figure 6. PGE2 inhibited global protein synthesis, sup-
pressed the mTOR pathway, and enhanced activation of
rpS6 in mouse PMs. PMs were harvested by lavage from
naive C57BL/6 mice and were plated in serum-containing
RPMI medium at 3–5  106 cells/ml for 2 h. A) PGE2-
induced suppression of global protein synthesis in mouse
PMs. After 2 h incubation in serum-containing medium,
mouse PMs were washed twice with methionine- and se-
rum-free medium and then were cultured for 1 h in the
medium, with or without PGE2 (1 M). Methionine analog
AHA was added to each well at a final concentration of 25
M, and cells were further incubated with AHA for 40 min.
Then, cell lysates were harvested, and the Click-iT reaction
was performed on the cell lysates to conjugate biotin to
AHA analog incorporated into newly synthesized proteins.
After electrophoresis of cell lysates, newly synthesized proteins containing biotin-conjugated AHA were detected with
streptavidin-HRP. Left panel: representative immunoblot. Right panel: densitometry results from 3 experiments. Densi-
tometry of the entire lane was expressed relative to that in control without any treatment (expressed as 100%, dashed line)
in each experiment. *P  0.05 vs. control without PGE2 treatment. B) PGE2 suppressed the mTOR pathway while
enhancing activation of rpS6 in mouse PMs. After 2 h incubation in serum-containing medium, cells were washed twice with
serum-free medium to remove nonadherent cells and then were incubated in the medium, with or without PGE2 (1 M)
or rapamycin (Rapa, 1 M). At the indicated time points, cell lysates were harvested, and levels of phosphorylated S6K1 and
rpS6 in the lysates were determined by immunoblot analysis. Immunoblot representative of 3 experiments is shown. C) Summary of
the findings. PGE2, via PKA, activates rpS6 while suppressing the mTORC1 pathway; both actions contribute to inhibition
of protein translation
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function by PGE2. Although PGE2 and cAMP have been
reported in some experimental systems to increase
activation of mTORC1 (36, 37), the suppressive actions
observed in our system are consistent with other reports
of inhibition of mTORC1 by cAMP (38, 39) and by PKA
(39, 40) in cell types other than the fibroblasts and
macrophages used in the current study.
It is unclear whether the suppression of mTORC1
reflects a direct or indirect action of PKA. PKA regula-
tory subunit I has been reported to colocalize with
mTOR (40), and cAMP-PKA has been noted to cause
dissociation of mTORC1 (39). Both of these actions
were associated with suppression of mTORC1 activity.
Alternatively, it is possible that PGE2-PKA indirectly
opposes mTORC1 activity via phosphatase activation.
For example, we have shown that PGE2 enhances fibroblast
activity of phosphatase and tensin homologue deleted
on chromosome 10 (PTEN; refs. 8, 11), a phosphatase
that suppresses fibroblast survival and activation by
opposing the PI3 kinase/Akt pathway. Akt is an up-
stream activator of mTORC1 (18), and it is possible that
PGE2 indirectly suppresses mTORC1 activity by PTEN-
mediated suppression of Akt signaling. A similar out-
come could result from PGE2-PKA activation of Src
homology domain 2–containing phosphotyrosine
phosphatase (SHP)-2, since SHP-2 is activated by PKA
(41) and also down-regulates mTORC1 activity, possibly
through a well-known negative regulator of mTORC1,
5=-AMP-activated protein kinase (42).
PGE2 appeared to differentially inhibit translation of
individual proteins, as evidenced by the electrophoretic
patterns observed in Fig. 3A and by the fact that procollagen
I protein was reduced to a greater degree than was total
protein synthesis. Differential modulation of transla-
tion of specific mRNAs is consistent with emerging
themes in translational control (43–45), but little is
known about how such differences are manifested. On
the basis of our results, we speculate that mTORC1 and
rpS6 checkpoints, which are modulated differently by
rapamycin vs. PGE2, control translation of distinct
groups of transcripts.
PGE2 influences a myriad of functions of diverse
target cells. The ability of PGE2 to regulate translation
extends its repertoire of regulatory actions, which al-
ready includes modulation of transcription factor ex-
pression and activation (46, 47), of DNA methylation
(12, 48), and of protein secretion (49). Several lines of
evidence point to the importance of translational con-
trol in the evolution of fibrotic disease (43, 50). The
findings described in this report provide a new para-
digm for understanding the role of PGE2 as a brake on,
and a potential treatment for, fibrotic diseases. Further-
more, in view of the pleiotropic actions of mTOR in
controlling cellular energy balance and metabolism, its
inhibition by the mediator PGE2, a mediator whose
synthesis is itself altered in numerous pathophysiologic
processes and by commonly used medications, opens
new avenues for understanding cell function in a
clinical context.
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